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Insulin-induced improvement of postischemic recovery is
abolished by inhibition of protein kinase C in rat heart
Ulrich Fischer-Rasokat, BS
Torsten Doenst, MD
Objective: We demonstrated earlier that postischemic addition of insulin improves
recovery of function in isolated rat heart by phosphatidylinositol 3-kinase. Activa-
tion of phosphatidylinositol 3-kinase before ischemia improves recovery of the heart
after ischemia through protein kinase C. We tested whether protein kinase C
activation is required for the positive inotropic effect of insulin during reperfusion.
Methods: Isolated working rat hearts were perfused with Krebs-Henseleit buffer
containing [2-3H]glucose (5 mmol/L, 0.05 Ci/mL) plus oleate (0.4 mmol/L) and
were subjected to 15 minutes of global ischemia followed by 35 minutes of
reperfusion with or without insulin (1 mU/mL). We measured cardiac power,
glucose uptake, and tissue metabolites. The protein kinase C inhibitor chelerythrine
(5 mol/L) was added either at the beginning of the experiment or together with
insulin. Experiments were repeated under normoxic conditions.
Results: Cardiac power before ischemia was 9.63 to 12.4 mW. Insulin improved
recovery of power after ischemia (96.3%  10.8% versus 65.7%  3.79%, P 
.05). This effect was abolished by chelerythrine (55.3%  6.49%). However,
chelerythrine given at reperfusion did not block insulin’s effect on recovery (101.0%
 4.25%, P .05). Postischemic glucose uptake was not increased by insulin (3.07
 0.32 before, 3.45  0.34 mol/min/gdw after ischemia, not significant) and was
not affected by chelerythrine (3.01  0.26 before, 3.29  0.32 mol/min/gdw after
ischemia, not significant). Under normoxic conditions, chelerythrine did not influ-
ence insulin’s effects on glucose uptake or power.
Conclusion: The results suggest that (1) insulin’s effect on recovery is dependent on
ischemia-induced protein kinase C activation, (2) the activity of protein kinase C
during reperfusion may not be important for this effect of insulin, and (3) protein
kinase C plays no role in insulin’s effect on glucose uptake under normoxic or
postischemic conditions.
Insulin improves postischemic contractile function of the heart in bothexperimental and clinical situations.1,2 The mechanisms discussed for thiseffect include modulation of postischemic substrate utilization,3 systemicvasodilation,4 and direct effects of insulin on the heart.1,5 We demonstratedpreviously that insulin directly improves postischemic cardiac power of theisolated working rat heart without affecting glucose uptake or glucose or
fatty acid oxidation.1 We recently found that the positive inotropic effect of insulin
is mediated through phosphatidylinositol 3-kinase (PI3K), which is not associated
with an increase in glucose uptake.6
PI3K also plays a role in the mechanism of ischemic preconditioning where it is
activated preischemically, which in turn leads to activation of protein kinase C
(PKC).7 Activation of PKC, 1 of the 2 major isoforms in adult rat hearts, was
shown to be required and sufficient to improve postischemic cardiac function of
transgenic mice and to reduce ischemic cell damage in isolated rat hearts.8,9 In
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analogy to ischemic preconditioning, we speculated that the
postischemic positive inotropic effect of insulin may also be
mediated by PKC.
PKC has also been demonstrated to interfere with insulin
signaling, affecting metabolic pathways.10 We therefore
wanted to assess whether the lack of insulin’s ability to
stimulate glucose uptake after ischemia could be attributed
to PKC activation.
Finally, the timing of PKC activation appears to be
important for its mode of action.11 To obtain information
about potential differential effects of PKC activation at
different time points, we blocked PKC either throughout the
experiments or only during reperfusion.
We found that the postischemic positive inotropic effect
of insulin is dependent on ischemia-induced PKC activation
but that the activity of PKC during reperfusion may not be
important for this effect of insulin. We also found that PKC
does not play a role in insulin’s effect on glucose uptake
either under normoxic or under postischemic conditions.
Methods
Animals
Male Sprague-Dawley rats (260-370 g, n  51) were obtained
from Charles River (Sulzfeld, Germany) with free access to food
and water. Animals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals, and the use of
animals and the experimental protocols were approved by the
Animal Welfare Committee of the University of Freiburg, Ger-
many.
Materials
Chemicals, enzymes, and cofactors were obtained from Sigma
Chemical Co (Deisenhofen, Germany), MERCK (Darmstadt, Ger-
many), or Roche (Mannheim, Germany). Regular human insulin
(Actrapid) was obtained from Novo Nordisk (Mainz, Germany).
Bovine serum albumin (BSA), Cohn fraction V, fatty acid free was
obtained from Intergen Company (Purchase, NY).
Radioisotopes and Glucose Uptake
High-performance liquid chromatography-purified [2-3H]glucose
was obtained from NEN Life Science Products (Cologne, Ger-
many). The purity of the tracer was verified by measuring the
intrinsic 3H2O content. The tracer was discarded if the intrinsic
water content was 1% of the total activity. Glucose uptake was
determined by the rate of 3H2O production from [2-3H]glucose as
described previously.12
Working Heart Preparation and Contractile
Performance
The preparation has been described elsewhere in detail.13 Hearts
were perfused as working hearts at 37°C with recirculating Krebs-
Henseleit buffer (200 mL) containing glucose (5 mmol/L) and
Na-oleate (0.4 mmol/L) bound to 1% BSA and equilibrated with
95% O2–5% CO2. Perfusate [Ca2] was 2.5 mmol/L. All experi-
ments were carried out with a preload of 15 cm H2O and an
afterload of 100 cm H2O. All hearts were beating spontaneously.
Aortic flow and coronary flow were measured every 5 minutes and
cardiac output was calculated as the sum of both values. Heart rate
as well as systolic and diastolic aortic pressures were measured
continuously with a pressure transducer connected to a physiologic
recording device (Hugo Sachs Elektronik, Umkirch, Germany).
Cardiac power was determined from the product of cardiac output
and mean aortic pressure:
Cardiac power

Mean aortic pressure (cm H2O)  cardiac output (mL/min)
620
Recovery was assessed by calculating average cardiac power dur-
ing reperfusion and comparing that to average cardiac power
before ischemia, which corrects for potential intraindividual dif-
ferences in preischemic cardiac power of the hearts.
Perfusion Protocol
Hearts were perfused according to 1 of 11 perfusion protocols.
Figure 1 shows a schematic of the 5 normoxic and 6 ischemic
protocols. Isolated working rat hearts were perfused with Krebs-
Henseleit buffer containing glucose (5 mmol/L, [2-3H]glucose
0.05 Ci/mL) plus oleate (0.4 mmol/L bound to 1% BSA). In the
ischemia protocols (Figure 1, B), 20 minutes of normoxic perfu-
sion were followed by 15 minutes of total, global, normothermic
ischemia and 35 minutes of reperfusion with or without insulin (1
mU/mL). Chelerythrine was dissolved in a 20 mmol/L dimethyl-
sulfoxide stock solution and was given either at the beginning of
the experiment or after ischemia alone or together with insulin at
an end concentration of 5 mol/L. At this concentration, chel-
erythrine fully inhibits all forms of PKC without affecting other
protein kinases.14 At the end of the experiments, hearts were
freeze-clamped to determine levels of glycogen, glucose 6-phos-
phate, and lactate. The experimental protocols were repeated under
normoxic conditions (Figure 1, A).
Statistical Analysis
All data are presented as mean SEM. Statistical comparison was
made using repeated measures analysis of variance or unpaired
analysis of variance with post hoc comparison by Newman-Keuls
test as appropriate.15 Differences were considered statistically
significant when P  .05. As the statistical power of the main
differences was high, the number of experiments per group was
limited to 3 to 6.
Results
Normoxia
Table 1 shows cardiac power of hearts under normoxic
conditions. During the first 30 minutes of the experiments
cardiac power ranged from 7.94 0.82 to 10.8 1.32 mW.
When chelerythrine was present in the perfusate from the
beginning of the experiments, cardiac power was higher
than in the other groups (P  .01). However, in all exper-
imental groups cardiac power remained stable throughout
the experiments and was not affected by any of the inter-
ventions.
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Glucose uptake (Table 2) in the first 30 minutes ranged
from 2.60  0.18 to 3.11  0.48 mol/min/gdw and was
the same in all groups. Chelerythrine did not affect glucose
uptake. Insulin caused a significant increase in glucose
uptake in all groups. Chelerythrine had no influence on this
effect either. In the groups where chelerythrine was given
alone either at the beginning or after 30 minutes, glucose
uptake was lower during 30 to 60 minutes than during the
first 30 minutes. This is unlikely to be chelerythrine’s effect
because addition of chelerythrine at the beginning (N-
Chel[0]) did not affect glucose uptake during the first 30
minutes.
Ischemia
Table 3 shows cardiac power of hearts before ischemia
and during reperfusion. Figure 2 shows the recovery of
contractile function in percent of preischemic power.
Hearts generated between 9.48  0.59 and 12.4  0.72
mW before ischemia. Again, cardiac power was higher
compared with the control group when chelerythrine was
present from the beginning of the experiment. Contractile
function remained significantly suppressed in the control
group during reperfusion. Insulin given at the beginning
of reperfusion improved postischemic function to near
normal values. Addition of chelerythrine alone either at
Figure 1. Experimental protocols for hearts perfused under normoxic conditions (A) or subjected to 15 minutes of
total, global, normothermic ischemia (B). All hearts were perfused at physiological workload with Krebs-Henseleit
buffer containing glucose (5 mmol/L) and oleate (0.4 mmol/L) as substrates and were freeze-clamped at the end of
experiments. Chelerythrine (5 mol/L) or insulin (1 mU/mL) or both were present in the perfusate for the indicated
time periods.
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the beginning of the experiments or after ischemia did not
influence recovery of function. Chelerythrine fully inhib-
ited the effects of insulin on recovery when given at the
beginning of the experiments. Chelerythrine did not
block insulin’s effect on recovery when given at the end
of ischemia.
Glucose uptake before ischemia ranged from 2.74 
0.13 to 3.29  0.27 mol/min/gdw with no differences
among groups and did not differ from baseline glucose
uptake in the groups under normoxic conditions. After isch-
emia, the glucose uptake measured in each group did not
differ from the corresponding glucose uptake measured
before ischemia.
Tissue Metabolites
Table 4 shows tissue contents of glycogen, glucose-6-phos-
phate (G6P), and lactate at the end of the experiments.
Glycogen content was higher in hearts perfused under nor-
moxic conditions than in hearts subjected to ischemia/reper-
fusion. Glycogen content was lowest in postischemic hearts
where chelerythrine was present from the beginning of the
experiment. Under normoxic conditions G6P content was
lowest when chelerythrine was given after 30 minutes.
There were no differences in G6P content among groups
after ischemia. Lactate content was highest in the control
group’s postischemic hearts.
Discussion
We have shown that (1) the effect of insulin on recovery of
contractile function is dependent on ischemia-induced PKC
activation, (2) the activity of PKC during reperfusion may
not be important for this effect of insulin, and (3) PKC plays
no role in insulin’s effect on glucose uptake either under
normoxic or under postischemic conditions.
Inhibition of PKC before but not after ischemia abol-
ished the postischemic, positive inotropic effect of insulin
on recovery of contractile function. This was in contrast to
our initial hypothesis that insulin affects postischemic con-
tractile function by PI3K-activated PKC. Our observations
could be due to at least 2 different scenarios. First, it is
conceivable that the time required for PKC inhibition by
chelerythrine is longer than the time insulin takes to activate
PKC. Though we did not measure the PKC activity in this
study, this explanation seems rather unlikely because the
mechanism of PKC inhibition by insulin suggests a rather
fast onset of action14 (see below). The second and more
likely scenario is that PKC is not part of the postischemic
insulin pathway, although PKC activation is required for
insulin’s effect on recovery of function. This speculation is
supported by observations of PKC activation during isch-
emia. PKC isoforms , 1/2, , , and  have been identified
in rat heart.16 Ischemia results in the activation of the major
TABLE 2. Glucose uptake in the first and second half of the
experiments under normoxic conditions*
Group
Glucose uptake (mol/min/g dry wt)
0-30
minutes
30-60
minutes
N-Ins 2.60 0.18 3.55 0.38†
N-Chel(0) 2.66 0.25 1.89 0.29‡
N-Chel(30) 2.88 0.41 2.25 0.26‡
N-Chel(0)Ins 3.11 0.48 4.16 0.62†
N-Chel(30)Ins 2.72 0.52 4.07 0.72†
*Values are mean SEM and represent the average glucose uptake in the
respective time period (n  3 to 5 per group). Hearts were perfused for 60
minutes under normoxic conditions. Insulin (Ins, 1 mU/mL) was added after
30 minutes. Chelerythrine (Chel, 5 mol/L) was added at the beginning of
the experiment (0) or after 30 minutes (30).
†P  .01 versus 0 to 30 minutes.
‡P  .05.
TABLE 3. Cardiac power before ischemia and during
reperfusion*
Group
Cardiac power (mW)
Before ischemia
(0-20 minutes)
During reperfusion
(35-70 minutes)
I-Control 9.63 0.51 6.42 0.64‡
I-Ins 10.4 1.08 9.64 0.60
I-Chel(0) 12.4 0.72† 7.99 1.43‡
I-Chel(35) 9.48 0.59 7.04 1.02§
I-Chel(0)Ins 12.0 0.54† 6.66 0.90‡
I-Chel(35)Ins 9.56 1.16 9.69 1.38
*Values are mean  SEM and represent the average contractile perfor-
mance in the respective time period (n  4 to 6 per group). Insulin (Ins, 1
mU/mL) was added at the beginning of reperfusion. Chelerythrine (Chel, 5
mol/L) was added at the beginning of the experiment (0) or during
reperfusion (35). See Figure 1 and text for details.
†P  .05 versus I-Control and I-Chel(35)
‡P  .01 versus before ischemia.
§P  .05.
TABLE 1. Cardiac power in the first and second half of the
experiments under normoxic conditions*
Group
Cardiac power (mW)
0-30
minutes
30-60
minutes
N-Ins 7.94 0.82 8.06 0.81
N-Chel(0) 10.6 1.28† 9.85 1.58†
N-Chel(30) 8.72 0.68 8.57 0.57
N-Chel(0)Ins 10.8 1.32† 10.8 1.15†
N-Chel(30)Ins 8.87 1.21 8.77 1.28
*Values are mean  SEM and represent the average contractile perfor-
mance in the respective time period (n  3 to 5 per group). Hearts were
perfused for 60 minutes under normoxic conditions. Insulin (Ins, 1 mU/mL)
was added after 30 minutes. Chelerythrine (Chel, 5 mol/L) was added at
the beginning of the experiment (0) or after 30 minutes (30).
†P  .01 versus all other groups.
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isoforms , , , and  during short episodes of ischemia and
specific activation of PKC  and  after prolonged episodes
in isolated perfused rat hearts.17 One could speculate that
the ischemic activation of PKC is crucial in insulin’s
postischemic effect, because (1) PKC is activated during
short and long episodes of ischemia,17 (2) the number of
atypical isoforms in adult rat heart is negligible,18 and (3)
the -isoform of PKC is a key mediator of protection of
infarct size and recovery of function afforded by ischemic
preconditioning.8,19,20 The observation that PKC inhibition
during ischemia but not during reperfusion abolishes the
insulin effect is striking because it suggests that PKC may
modulate a component in the insulin signaling cascade,
which then mediates the positive inotropic effect. The PKC
activity during reperfusion does not seem to play a role in
this effect. This conclusion receives support from a recent
study by Simonis and colleagues,11 who show PKC playing
a comparable role in ischemic preconditioning. Brief isch-
emic episodes lead to PKC activation and translocation,
which were reversed during the reperfusion periods and
which were undetectable during a third ischemic period.
The authors conclude that sustained activation of PKC is no
prerequisite for preconditioning.
We used the nonselective PKC inhibitor chelerythrine in
this study. The IC50 of chelerythrine for PKC inhibition is
0.66 mol/L. The IC50 for other protein kinases (PKA,
TPK, Ca/CM-PK) is 0.1 mmol/L.14 Thus, at the con-
centration of 5 mol/L we used, PKC should be fully
inhibited, with no significant inhibition of other protein
kinases. This conclusion is supported by the work of Davies
and coworkers.21 Chelerythrine interferes with the catalytic
site of the enzyme, which is present in all isoforms. From a
kinetic standpoint, we cannot exclude that chelerythrine,
when given together with insulin after ischemia, takes
longer to inhibit PKC than insulin does to activate PKC.
However, delayed PKC inhibition by chelerythrine seems
unlikely because the mechanism of PKC inhibition suggests
a rather fast onset of action.14 We also experimented with
staurosporine initially, a different type of PKC inhibitor.
However, staurosporine exhibited a significant negative ino-
tropic effect that prevented the hearts to generate the re-
quired afterload.
Addition of chelerythrine right at the beginning of the
experiments unexpectedly resulted in the hearts’ best per-
formances. In these experiments cardiac performance was
stable throughout the entire experiment under normoxic
conditions. Under postischemic conditions, hearts showed a
decrease in cardiac power comparable to the control group.
The significance of this observation is not clear at this time.
It is conceivable that PKC-isoforms whose inhibition in-
creases cardiac power are activated during preparation of
the hearts in ice-cold KH-buffer. Thus, the increase in
cardiac power by chelerythrine may therefore be a feature of
the isolated working rat heart. However, no changes in
cardiac function were observed when chelerythrine was
given later during the experiments. Therefore it is unlikely
Figure 2. Postischemic recovery of contractile function in percent of preischemic power of hearts subjected to the
ischemic protocols (see Figure 1, n  4 to 6 per group). Insulin (Ins, 1 mU/mL) was added at the beginning of
reperfusion. Chelerythrine (Chel, 5 mol/L) was added either at the beginning of the experiment (I-Chel(0)) or at
the beginning of reperfusion (I-Chel(35)). See text for details. Values are mean  SEM. *P < .05 compared with
control.
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that postischemic cardiac power was influenced by unspe-
cific effects of chelerythrine.
In preliminary studies, we attempted to perfuse hearts
with the phorbol ester phorbol 12-myristate 13-acetate
(PMA) to mimic ischemia-induced PKC-activation. How-
ever, as with staurosporine, the PKC activation by PMA in
effective concentrations was also associated with a signifi-
cant negative inotropic effect, which did not allow reliable
perfusions of the hearts (data not shown). We believe that
the inability to use the drug in our model may be associated
with our isolated working rat heart preparation. This has
also been observed by others who demonstrated a negative
inotropic effect of PMA or other PKC activators such as
1,2-dioctanoyl-sn-glycerol (DOG) in the isolated rat
heart.22,23 The full elucidation of the underlying mechanism
may therefore require the use of a different experimental
model.
To assess whether metabolic effects of insulin may con-
tribute to the postischemic effects of insulin on contractile
function, we measured glucose uptake and determined the
tissue content of those metabolites affected by insulin (ie,
glycogen, glucose-6-phosphate, and lactate). The effect of
insulin on recovery of contractile function was independent
of its effects on glucose uptake and of the measured metab-
olites. Although the addition of insulin resulted in recovery
of function to near basal values, insulin was not able to
increase glucose uptake. We have demonstrated already a
postischemic positive inotropic effect of insulin where in-
sulin did not affect glucose or fatty acid oxidation.1 Here we
provide further evidence for our hypothesis, namely that the
effect of insulin on contractile function is direct rather than
secondary to modulations of substrate metabolisms. This
conclusion is supported by a lack of major changes in tissue
metabolites by insulin measured at the end of the experi-
ments. Under normoxic conditions, insulin increases glu-
cose uptake and does not affect contractile function in the
isolated working rat heart. It is interesting to note in this
context that administration of glucose-insulin-potassium in-
fusion to patients after cardiac surgery improves cardiac
function and reduces mortality at a time where insulin
responsiveness is severely diminished.24 Thus, it appears
that ischemia induces a shift in insulin responsiveness from
mainly metabolic to contractile effectors. Such an effector
may be the L-type Ca-channel. It has recently been demon-
strated that the L-type Ca-channel is directly activated by
insulin in a dose-dependent manner.25 This mechanism may
be potentially responsible for insulin’s positive inotropic
effect.
PKC has been demonstrated to inhibit the insulin recep-
tor.10,26 PKC activation in this context may occur through
ischemia-induced accumulation of free fatty acids27 and
may be responsible for the clinically observed state of
insulin resistance. We observed a state of insulin resistance
with respect to glucose uptake in hearts after ischemia.
However, it is unlikely that inhibition of the insulin receptor
by PKC is responsible for this effect for 2 reasons. First,
inhibition of PI3K in previous experiments abolished insu-
lin’s effect on contractile function after ischemia,6 suggest-
ing that the proximal part of the insulin signaling cascade is
still intact under these conditions. Second, the PKC inhibi-
tion did not reinstate insulin’s effect on postischemic glu-
cose uptake, so that PKC is unlikely to mediate mechanisms
inhibiting insulin-stimulated glucose uptake. Unexpectedly,
chelerythrine was not able to block insulin-induced glucose
uptake under normoxic conditions, which may reflect the
minor expression of atypical isoforms in adult rat hearts. We
found the lowest glycogen content in hearts where chel-
erythrine had been given from the beginning of the exper-
iments. However, none of the groups differed significantly
from the control group. Interpreting these differences is
difficult because we did not determine glycogen content
before and at the end of ischemia in our experiments. It is
important to realize in this context that glycogen turnover is
more important with respect to contractile function than
glycogen content at the end of the experiments.28,29
We have recently shown that insulin improves recovery
of function through PI3K,6 and we demonstrate here that
PKC activation is also required for this effect. Both en-
zymes are also involved in the mechanism of ischemic
preconditioning, which is known as the most powerful
TABLE 4. Tissue contents of glycogen, glucose-6-phos-
phate, and lactate of hearts at the end of the experiments*
Group
Metabolites (mol/g dry wt)
Glycogen Glucose-6-phosphate Lactate
Normoxia
N-Ins 128.2 3.10 1.53 0.11 3.88 0.70
N-Chel(0) 126.6 13.3 1.20 0.18 2.35 0.35
N-Chel(30) 114.4 5.55 0.96 0.17‡ 3.05 0.81
N-Chel(0)
Ins
137.0 10.6 1.55 0.05 3.69 0.55
N-Chel(30)
Ins
125.7 13.4 1.71 0.02 3.21 0.05
Ischemia
I-Control 90.8 7.57 1.65 0.14 4.81 0.56§
I-Ins 97.5 6.81 1.40 0.16 3.47 0.36
I-Chel(0) 73.3 7.73 1.19 0.16 2.76 0.31
I-Chel(35) 91.3 5.13 1.21 0.15 2.88 0.14
I-Chel(0)
Ins
67.4 3.18† 1.23 0.12 4.12 0.27
I-Chel(35)
Ins
115.9 13.1 1.68 0.08 3.04 0.49
*Values are mean  SEM and represent the average tissue content of the
metabolites at the end of the experiments under normoxic and ischemic
conditions.
†P  .05 versus I-Ins and I-Chel(35)Ins.
‡P  .05 versus N-Ins, N-Chel(0)Ins, and N-Chel(30)Ins.
§P  .05 versus other groups except I-Chel(0)Ins.
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method to protect hearts from subsequent ischemia. The
greatest handicap in the use of ischemic preconditioning is
the need for pretreatment, excluding its clinical use in
situations of unexpected acute ischemia (myocardial infarc-
tion). In these situations insulin can be given postischemic-
ally. Our results suggest a similar link between ischemic
preconditioning and the insulin-induced improvement of
postischemic cardiac power. It is conceivable that observa-
tions made by us and others7 may differ because of the
involvement of different isoforms of PKC and/or PI3K.
However, if the observations should describe the same
mechanisms, this conclusion would give rise to the intrigu-
ing speculation that the protective mechanism of ischemic
preconditioning may be exploited by activating the insulin
signaling cascade at the end of ischemia.
We conclude that the postischemic positive inotropic
effect of insulin is dependent on ischemia-induced PKC
activation and that the activity of PKC during reperfusion
may not be important for this effect of insulin. We found
that PKC plays no role in insulin’s effect on glucose uptake
either under normoxic or under postischemic conditions.
This means that insulin has a direct effect on contractile
function after ischemia, which is mediated through a path-
way that differs from the conventional signaling cascade by
requiring ischemic PKC activation.
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